Blog Post
Ondansetron ODT Granted
Healthcare Pharma • 18 December 2018
The MHRA has approved our licence application for Ondansetron 4mg and 8mg Orodispersible Tablets. The tablets are indicated in adults for
- management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy
- prevention of post-operative nausea and vomiting(PONV)
This is the first Marketing Authorisation submitted under the Healthcare Pharma banner.
Detailed prescribing information is available at www.medicines.org.uk/emc
We are pleased to announce the launch of losartan tablets. Product details are as follows:
Healthcare Pharma are pleased to announce that they have partnered with JCS Pharma to develop a range of generic products. Leveraging JCS Pharma's product development expertise, we are focussing on the development of a variety of different pharmaceutical products for various therapeutic areas. For more information about JCS Pharma, visit their website: https://jcspharma.co.uk/
We are pleased to announce the launch of azathioprine tablets. Product details are as below:
We're delighted that Sharon Norcott has joined Healthcare Pharma. Sharon will be managing our sales processing and purchasing functions to support both our customers and suppliers. Sharon has a wealth of knowledge of the financial sector, her last role being an Accounting Operations Manager. So she is certainly at ease operating within highly regulated environments. We wish her all the best in the new role.
We are delighted to have been successful in the latest round of contracts for supplying NHS hospitals in England with generic medicines. The NHS National Generic Pharmaceuticals Contact is awarded to companies who are best able to deliver high quality generic medication at competitive prices and in an efficient manner. So this is a real feather in our caps. Further information about the work of the Commercial Medicines Unit can be found at https://www.gov.uk/government/collections/commercial-medicines-unit-cmu
